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Abstract 
Cross-species comparison has long been regarded as a stepping stone for medical research, enabling the 
discovery and testing of prospective treatments before they undergo clinical trial on humans. Post-
genomic medicine has made cross-species comparison crucial in another respect: the ‘community 
databases’ developed to collect and disseminate data on model organisms are now often used as a 
template for the dissemination of data on humans and as a tool for comparing results of medical 
significance across the human-animal boundary. This paper identifies and discusses four key problems 
encountered by database curators when integrating human and non-human data within the same 
database: (1) picking criteria for what counts as reliable evidence, (2) selecting metadata, (3) 
standardising and describing research materials and (4) choosing nomenclature to classify data. An 
analysis of these hurdles reveals epistemic disagreement and controversies underlying cross-species 
comparisons, which in turn highlight important differences in the experimental cultures of biologists 
and clinicians trying to make sense of these data. By considering database development through the 
eyes of curators, this study casts new light on the complex conjunctions of biological and clinical 
practice, model organisms and human subjects, and material and virtual sources of evidence – thus 
emphasising the fragmented, localized and inherently translational nature of biomedicine. 
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   ‘Man is the most unsatisfactory of all organisms for genetic study’  
A. Sturtevant 1954 
 
Introduction 
STS scholarship has long noted the important role played by online databases within scientific 
research. Large research efforts have been invested in the construction of databases (Wouters and 
Schroeder 2003, Hey and Trefhesten 2005, Stein 2008), resulting in major shifts in the ways in which 
scientific work is organized (Leigh Star and Rhleder 1996, Bowker 2001), ordered (Hine 2006) and 
communicated (Hilgartner 1995). The dissemination of data through electronic means is now an 
essential complement to traditional publication strategies and the consultation of databases has become 
part and parcel of everyday routines within experimental research (Lenoir 1999). The heightened need 
for specialist skills in computer programming has also affected the division of research labor and the 
ways in which scientists are trained. While university curricula in natural science are giving new 
prominence to information technologies, database ‘curators’ have emerged as a professional figure 
whose responsibilities lie in developing databases that satisfy the needs of prospective user 
communities (Leonelli 2009; Baker and Millerand 2010; Chow-White and Garcia-Sanchos, 2011). The 
impact of online resources is particularly evident within the biological and biomedical sciences, where 
research communities dedicated to the study of popular model organisms have developed sophisticated 
databases for the organization, dissemination and comparative analysis of genomic data coming from 
different species (Leonelli 2010a). These tools are often treated as a model for how cross-species data 
mining should be organized. This has special relevance for the development of information 
infrastructures for post-genomic, molecular-based medicine, which requires digital platforms through 
 
 
which data on human and non-human organisms can be integrated and compared. Indeed, the databases 
developed within model organism biology have been hailed as critical to ‘unlocking the very essence of 
biologic life and enabling a new generation of medicine’ (Buetow 2005). Databases are expected to 
facilitate the achievement of these ambitious goals by fostering the integration of biological and 
biomedical knowledge, and thus supporting translational research towards new forms of medical 
diagnosis and treatment.  
This paper investigates the role played by databases within biomedical research through an 
examination of the practical difficulties encountered by database curators in fulfilling such huge 
expectations. The hype attached to database development as an easy solution to the current ‘data 
deluge’ has taken attention away from the problems involved in actually using data found online 
towards further research: in particular, from the difficulties of matching in silico representations of the 
world with experimentation in vivo and clinical intervention, and aligning the experimental practices 
characterizing research on humans with the ones used to research model organisms. I here propose to 
view the process of database development not primarily as a means towards the solution of those 
problems (thought this might certainly be the case), but rather as an excellent site where diverging 
stakes, values and epistemologies characterizing experimental cultures in biomedicine can be identified 
and discussed. The idea for this paper emerged from in-depth conversations which I carried out with 
the curators of several major sites primarily devoted to collecting and disseminating data on model 
organisms, including The Arabidopsis Information Resource, WormBase, FlyBase, the Gene Ontology 
Consortium and the General Model Organism Database. These conversations, which took place 
between 2004 and 2010 in the context of research on the epistemology of model organisms, brought to 
my attention the acute discomfort that many curators felt at the perceived shortcomings of their 
databases. In particular, I found that curators worried about developing databases containing both 
human and non-human data. In what follows, I analyze some of the sources of that worry and show 
 
 
how it relates not simply to differences in the biology of the organisms being studied, but rather to 
differences in how biologists and clinicians conduct research, collect data and interpret their findings.i  
 
The use of cross-species databases is an excellent instance of ‘biomedicine’, defined as the set of 
practices which brings biological and clinical knowledge and techniques to bear on each other (Keating 
and Cambrosio 2003). Historians and sociologists of medicine have long pointed to the extensive 
fragmentation characterizing the epistemic communities involved in biomedical research and have 
analyzed the complex relations and intersections between them (e.g. Loewy 1986, Quirke and 
Gaudillière 2008). In particular, STS scholarship has documented how scientists attempt to overcome 
this pluralism in order to achieve common standards and procedures, for instance in the case of clinical 
trials (Kohli-Laven et al 2011), the trading of biological data and materials (Parry 2004), and the 
standardization of microarray experiments (Rogers and Cambrosio 2007). Database curation is another 
area where the introduction of standards, norms and specific technologies clashes with a highly 
fragmented and localized landscape of research habits and practices. This holds especially when 
considering the materials – the organisms - on which data are produced and disseminated. While it is 
tempting to neatly define clinical research as conducted exclusively on humans, much clinical work 
involves the collection and use of data acquired on rats, mice and other, more distant relatives of Homo 
sapiens (Davies 2010; Spradling et al 2006). Similarly, biological research largely revolves around few 
key model organisms, such as the nematode Caernorhabditis elegans, the fruit-fly Drosophila 
melanogaster, the plant Arabidopsis thaliana and the zebrafish Danio rerio (Davies 2004); and yet, 
biologists do not refrain from using human data whenever needed to further their understanding. 
Database curators are well aware of their important role in facilitating the comparison and integration 
of data on humans with data on model organisms. They are also aware that the success of their products 
depends on how useful they prove to be to experimenters, as this determines the levels of funding and 
 
 
community support that they will receive. Thus, the career of curators depends at least in part on their 
ability to identify, embrace and constructively engage as many epistemic cultures in biomedicine as 
possible; which, in practice, means making their digital representation of data at least compatible with, 
and at best conducive to, widely diverse forms of intervention on actual organisms. This inescapable 
commitment makes curators’ perspectives into very valuable sources of insight on the interface 
between biology and medicine and the experimental cultures that characterize those two highly 
intertwined, and yet distinguishable, realms. 
 
I start my analysis by discussing the emergence of cross-species databases, the conception of model 
organisms that they embody and the status of human data within them. I emphasize how curators of 
cross-species databases, who are mostly biologists rather than clinicians, find themselves treating 
humans as a model organism with no special epistemic status – that is, as yet another species on which 
we happen to have huge amounts of data that need to be compared with data from other species in 
order to provide biological understanding. I then single out four technical problems in the development 
of cross-species databases, which curators view as evidencing potential discrepancies between clinical 
and biological research practices: (1) the criteria for what counts as reliable evidence, (2) the selection 
of meta-data, (3) the standardization and description of research materials and (4) the choice of 
nomenclature used to classify data. In closing, I show how the controversies surrounding these aspects 
of database development reveal their significance in demarcating, and possibly reinforcing, epistemic 
differences between the lab and the clinic and between human and non-human research.  
 
Model Organism Databases and the Incorporation of Human Data 
Within model organism biology, huge efforts have been invested in database development over the last 
 
 
two decades (Bult 2006). On the one hand, these investments were certainly fuelled by the growing 
recognition, across biomedicine as a whole, that collection and dissemination practices affect whether 
and how data are re-used towards new discoveries (Buetow 2005). On the other hand, the extent to 
which model organism communities have engaged in database development is linked to their unique 
historical role in fostering a collaborative ethos within the notoriously competitive culture of 
biomedical research. Many of the most popular models, including the fruit-fly, the thale-cress, the 
nematode and the mouse, owe some of their success as laboratory organisms to the collaborative ethos 
and interdisciplinary ambitions fostered by the scientists who pioneered their use in biology (Kohler 
1994, Ankeny 2001, Leonelli 2007, Rader 2004).ii This emphasis on sharing was not simply a matter of 
individual commitment, but was actually essential to the research programs set up by biologists such as 
T. H. Morgan in the 1920s, Sydney Brenner in the 1960s and Chris Sommerville in the 1970s. Their 
explicit long-term goal was understanding organisms in all of their complexity through an 
interdisciplinary approach that would include genetics as well as cell biology, physiology, 
immunology, morphology and ecology; and their strategy to achieve this was to accumulate and 
integrate knowledge on the biology of one species, which would then provide a blueprint and reference 
point for comparative, cross-species research.iii Over the last two decades, this attitude has been 
incorporated into the building of model organisms databases, which are often referred to as 
‘community databases’ to stress their role in serving researchers by gathering and integrating all the 
information available on a specific organism of interest to them (Rhee and Crosby 2005). These 
databases, which are freely accessible online thanks to public funding from national and international 
agencies, have arguably become an important component of the very identity and status of model 
organisms in research, on a par with other characteristic features such as their capacity to represent 
other species, their tractability in the lab and the extent to which they embody biological processes of 
interest. Model organisms in the 21st century are organisms on which much is known, and knowledge 
 
 
of which can be freely and easily accessed and used to study other organisms (Ankeny and Leonelli 
2011). iv  
 
The Arabidopsis Information Resource (TAIR), the main database collecting data on Arabidopsis, is a 
good example of the success of this research strategy. Its first Director, Sue Rhee, is an eloquent 
advocate of the value of sharing resources (an approach she calls ‘share and survive’, as opposed to the 
‘publish or perish’ mentality characteristic of mainstream biomedical research; Rhee 2004) and set up 
TAIR as a platform for the collection and dissemination of all information of relevance to the study of 
Arabidopsis. Indeed, a decade after the end of the Arabidopsis sequencing project, this database 
provides access to several different types of data about the plant, as well as rich meta-data, search tools 
and modeling techniques to analyze the datasets and general information about the history of research 
on the plant. TAIR also co-operates with the Arabidopsis stock centers, which store hundreds of 
thousands of seed stocks of Arabidopsis mutants, so that users can order the specimens needed from 
their experiments directly from their website (Rosenthal and Ashburner 2002). As a result of these 
efforts, TAIR has become a key tool in plant science research and is routinely used to research not only 
Arabidopsis, but any other plant species, including crops. Other examples of well-curated and widely 
used community databases include FlyBase, WormBase, Mouse Genome Informatics and the Zebrafish 
Model Organism Database.v All of these databases were initially funded by public agencies to 
disseminate one specific type of data, that is the data coming out of sequencing projects; yet, they took 
advantage of the funding to build tools potentially incorporating other types of data on the same 
organism, and have aimed to increase the diversity of the data that they host ever since.vi 
 
These efforts to develop databases have resulted in curators acquiring a sophisticated understanding of 
 
 
the factors that influence the future adoption and use of data collected on model organisms across 
research contexts. These include the need to integrate different data types produced through various 
kinds of instruments and techniques, ranging from sequence data to photographs or tissue samples; to 
collect meta-data documenting the provenance of data; to develop representations of data that facilitate 
searches and the visualization of results retrieved from databases (e.g. maps, models, simulations); to 
be able to order the materials on which data were originally acquired, such as specimens of the same 
mutant; and to adopt intelligible keywords for the classification and retrieval of data. Curators have 
successfully proposed themselves as possessing the right skills to perform these complex tasks, and 
regular Biocurator meetings are now held across the globe to facilitate cooperation and interoperability 
across different databases (Howe et al 2008).  On the basis of their growing expertise and increasing 
need for comparative analyses, the curators of community databases have recently engaged in the 
development of several cross-species databases, where existing data on different organisms can be 
searched, viewed and compared. A well-known initiative of this kind is the Gene Ontology (GO), a 
bio-ontology developed jointly by the curators of several community databases for the cross-species 
annotation of gene products (Gene Ontology Consortium 2000). All the curators involved in GO hold a 
PhD in a branch of experimental biology, and use that expertise to inform their curatorial activities 
(they know what at least some of their users want, because they have been potential users themselves). 
The GO currently includes data from dozens of species, including several grains, yeast, slime mold, rat, 
several microbes and Homo sapiens, and is coordinated by a central office at the European 
Bioinformatics Institute near Cambridge, UK. Its funding depends largely on the public supports 
provided to the model organism databases involved in its development, which is why curators refer to 
GO as a ‘consortium’ of research efforts; further, a small National Human Genome Research Institute 
(NHGRI) grant supports the activities of GO coordinators in Cambridge.vii Another important initiative 
is the General Model Organism Database project (GMOD), also referred to as the ‘myriads’ database 
 
 
because of the sheer number of species that it incorporates. The GMOD project is again the result of an 
extensive cooperation involving over 100 participating databases, including repositories of human data 
such as Human 2q33, Chromosome 7 Annotation project, Xmap, Ymap and HapMap. The main goal of 
the GMOD is to help species-specific databases to coordinate their efforts, so as to guarantee 
interoperability across databases and thus facilitate cross-species analyses. To this aim, the GMOD 
encourages database curators to use a common set of software packages, such as tools for browsing and 
annotating genomes, and to take account of the standards already employed by the main model 
organism databases when setting up new tools and resources (http://gmod.org/wiki/Main_Page). One of 
the most used GMOD tools is the Generic Genome Browser, which has been adopted by several 
databases across the globe, including most community databases as well as HapMap and the Human 
Genome Segmental Duplication Database (Stein et al 2002). Before proceeding further, it is important 
to note how the funding allocated to both GO and GMOD compares to the large investments made in 
disease-specific databases. Cross-species databases are much less well-funded and rely on international 
cooperation much more than their purely medical counterparts. This feature might seem puzzling given 
the revolutionary results that these databases are expected to yield, but it becomes easy to understand 
given the current financial crisis and the pressure on scientific institutions to invest only in projects 
with short-term, measurable returns. Disease databases are deemed to be directly relevant to finding 
efficient treatments, and thus receive considerable support from both public and private institutions; 
while the contributions that cross-species databases could make to medical knowledge are much less 
clearly defined, and more difficult to understand and advertise to the general public, which results in 
scarce funding (mostly from public sources). 
 
Thanks to initiatives such as GO and GMOD, several features of the community databases developed 
within model organism research have been proposed as standards for the online gathering and 
 
 
distribution of all sorts of biological data, including data on humans. Indeed, the assimilation of human 
data into model organism databases has been fostered precisely for its potential value to both biological 
and medical research. The GMOD project itself is coordinated by the Ontario Institute for Cancer 
Research, where the International Cancer Genome Consortium is also based. Further, many community 
databases for model organisms, including the GMOD and GO projects, are sponsored by the National 
Human Genome Research Institute, with the following motivation: 
‘These bioinformatic resources will allow the scientific community efficient access to genomic 
data, which will enable new types of analyses. The analyses, in turn, will allow for the computer 
modeling and subsequent experimental validation of the complex pathways and networks that 
ultimately determine the phenotype of a cell or the causes of many human diseases’ (NIH 
website, accessed December 2009). 
 
So, at least in the context of biocuration, model organisms have become models for data mining in 
humans. This move was prompted by the technical expertise accumulated by biologists in 
disseminating data obtained from model organisms, which is viewed as immediately relevant also to 
human data; and yet, it is not obvious that such expertise is sufficient to coordinate the dissemination of 
data obtained through clinical research. The paradox of proposing to treat humans as a model organism, 
while at the same time acknowledging that this effort is not currently carried out in co-operation with 
human geneticists and clinicians, is captured by the following quote from a paper summarizing the 
discussions over the role of model organisms in understanding and treating human disease held at the 
2006 meeting of the Genetics Society of America: 
‘A critical need is better cross-organism databases that enable one to compare the genes, 
expression patterns, gene functions, cell types, tissue organization, and biological subprocesses 
 
 
across organisms, including humans. Maintaining and expanding our community resources, 
such as mutant collection and siRNA libraries for many organisms, including those not 
amenable to standard genetic techniques, is crucial. They provide access to the genetic power of 
the different model organisms and enable investigators to take full advantage of whole-genome 
sequence information. Finally, we must look for ways to interact with clinician scientists and 
human geneticists and bring their knowledge and perspectives to the modeling efforts’ 
(Spradling et al 2006). 
This quote clearly indicates that clinicians have not been involved with developing cross-species 
databases, and that this lack of involvement is potentially problematic and needs to be remedied. This 
situation is puzzling especially since one of the key purposes of cross-species comparisons is to achieve 
a better understanding of humans, leading to improvements in medical knowledge, diagnosis and 
treatments. In the words of a curator I interviewed in 2008,  
 ‘model organism databases also included human because obviously people are interested in 
what goes on in human, so that gets included even though there isn’t an organism database’. 
The curator is referring to the fact that there is no unique ‘model organism database’ for Homo sapiens 
(even if of course there are hundreds of disease / system / organ-specific human databases). There are 
several practical reasons for this: the sheer diversity and scale of data collecting practices on human 
beings; the multiplicity of sites where such collections are taking place, and the impossibility to 
coordinate and standardize the formats of collection; and the restriction to interoperability and access to 
human data, motivated by ethical concerns with privacy as well as by intellectual property issues in 
clinical research, particularly as carried out by pharmaceutical companies. If we stick to the above 
characterization of model organisms as ones on which data of all types, ranging from sequence data to 
morphological observations, can be collected and exchanged without restrictions, it is clear that Homo 
sapiens is not a model organism, nor could it become one in the future. Yet, as evident in the above 
 
 
quote, in the context of cross-species databases, human data are treated in the same way as data coming 
from model organisms. 
 
This observation opens a host of ethical questions about privacy concerns and the status of individuals 
and populations in biomedical research. These questions are being examined by scores of excellent 
social scientists, so I will not focus on them here. What I wish to explore is, rather, the differences in 
experimental practices characterizing human and non-human research that are brought to the fore by 
current attempts to develop cross-species databases. In what follows, I focus on four sets of issues that 
curators perceive to be emerging when human data are added to model organism databases: those 
concerning data, meta-data, materials and terminology. My analysis is based on a cross-examination of 
the content and guidelines of the GO and GMOD websites; and multi-sited ethnographic research on 
curation practices and database building carried out between 2004 and 2010, which included attendance 
at scientific meetings concerning biocuration in both model organism biology and medicine; visits to 
laboratories engaged in extensive bioinformatic work, including the development of cross-species 
databases; and extensive interviews with curators of cross-species databases based in the UK, Germany 
and the US. As a result of this long-term engagement, I have developed an ongoing dialogue with 
several curators, sometimes leading to collaborative activities (such as writing scientific papers 
together or inviting scientists to science studies meetings) and advisory roles within those communities 
(I am presently a member of the advisory board of the Genomic Network of Arabidopsis Research). 
My close personal and professional ties with database curator communities provide me with in-depth 
insight in their working habits and daily struggles, which as I will show is relevant to understanding the 
issues emerging when disseminating cross-species data. At the same time, this research methodology 
situates my analysis within the boundaries of my own interpretive understanding of a specific empirical 
context – which, as any ethnographic account, leaves open the question of whether these results capture 
 
 
other (understandings of) efforts to order and disseminate data. In particular, the concerns I shall voice 
are the ones expressed by curators trained in the biological sciences, who have had little or no exposure 
to clinical research. This is in itself a remarkable fact, underscoring the difficulties in involving clinical 
researchers in the curation of cross-species databases. The implication is that this study does not 
represent views held by clinicians and by curators involved solely in human databases, a shortcoming 
that I hope will be addressed through future empirical research. 
 
Issue 1: Data. What Counts as Reliable Evidence? 
The first issue I wish to highlight concerns a divergence in the criteria used to determine what counts as 
reliable evidence. The problem is exemplified by the unclear status of microarray data as a source of 
evidence about gene expression. A great deal of standardization of terminology, experimental protocols 
and instruments is required to describe a microarray experiment – and, at the same time, to make sure 
that the procedures and techniques used within such an experiment are intelligible and replicable across 
different laboratories. The MIAME project, which stands for Minimal Information About a Microarray 
Experiment, has been set up precisely to address this need and streamline the process of agreeing upon, 
and implementing, such standards. Still, the development of standards such as MIAME has been 
fraught with difficulties and controversies (Roger and Cambrosio 2007), and MIAME standards are 
still far from being widely applied. This means that the quality and reliability of microarray data is 
hotly contested. A recent review in Nature Genetics set out to evaluate the replicability of 18 datasets 
obtained through microarray experiment and found that ten could not be reproduced on the basis of the 
information provided. The conclusion was that ‘repeatability of published microarray studies is 
apparently limited. More strict publication rules enforcing public data availability and explicit 
description of data processing and analysis should be considered’ (Ioannidis et al 2009, 149). 
 
 
 
Despite remaining highly disputed,viii this kind of assessment provides the background to understand 
why several model organism databases do not accept microarray data as a valuable source of 
information about an organism. Many of the curators of these databases still view results of microarray 
experiments as highly dependent on the specific circumstances and expertise of the scientists who carry 
them out. The following quote exemplifies the feelings of several curators whom I interviewed on this 
subject: 
  ‘I’m doubtful that we would include any micro-array results at the moment. [..] You get very 
variable results from micro-array and you get lots of indications that genes are involved in 
certain processes when they may not be. They’re up-regulated because of various different 
reasons which may not be related to the experimental conditions that are used. So, yeah, they’re 
a bit doubtful’. 
 
In clinical settings, the variability and lack of experimental ‘validation’ of microarray data, which make 
them so problematic to accept within model organism science, do not seem to raise the same amount of 
skepticism.  While it is certainly true that the evidential value of genome-wide association studies is 
being widely debated, there is a widespread agreement that microarray experiments play an important 
role as sources of genomic evidence, especially since microarray results are being used in conjunction 
with other sources of evidence on the same genes/processes. The idea of experimental replication as a 
way to validate results is not as strong in clinical research as it is in biological research, for the simple 
reason that replicating experiments on the same tissues / humans is expensive, if it is at all possible 
given that samples are unique. Further, microarray experiments are seen to have an exploratory value: 
they can point to interesting correlations and patterns that might, upon further research, turn out to have 
biological meaning, yet they provide no clear evidence that those patterns exist, and would certainly 
not be trusted in isolation from other types of data.ix There is no intrinsic reason why this approach 
 
 
should not be equally powerful in the biological realm. However, curators perceive biologists as 
showing a low level of trust in results acquired by other researchers, and ideally wanting to be able to 
assess the reliability of microarray data on a case-to-case basis. This perception is illustrated by the 
following quote from a curator of a model organism database: 
  ‘It’s a tricky situation at the moment. Some people do annotate to high throughput experiments. 
We’re thinking about doing it, we haven’t done it as yet because we’re still working out how we 
would do it and to what extent we would go, because there are lots of experiments out there that 
maybe wouldn’t give very good results…very reliable results. But there are some certain high 
throughput experiments that are quite robust and so you would trust results you get. So we’re 
kind of in the process at the moment of deciding which experiments we would be happy to 
include’. 
 
Another interesting case of potential discrepancy between data mining in clinical and biological 
contexts concerns the ways in which data are extracted from publications. Several model organism 
databases rely on text-mining, or in some cases even manual annotation, to extract published data from 
available literature on a specific organism. This arduous task is made marginally easier by the existence 
of a rather coherent corpus of literature on each popular organism (Davies 2004). The situation is 
perceived to be different in clinical research on humans, as another curator relates: 
‘You kind of feel like ‘yeah, it would be nice if we had an organized set of human literature’, 
the kind of thing that FlyBase provides for Drosophila and that MGI provides for the enormous 
body of mouse literature. There are times when I feel like it would be nice if the sequence data 
and the transcript, you know, expression data and proteomic data and function data, the 
localization data were more unified. But the big one is the literature that I think is probably the 
biggest single thing that model organisms have because of model organism databases and that is 
 
 
missing from the systems that deal with the human genome sequence or human gene expression 
data’. 
It is worth noting that, while it is true that the publications on humans are so numerous and dispersed 
across disciplines to make it very difficult to assemble them together, this is due to the fact that medical 
research is organized in ways that differ widely from the typical set-up of a model organism 
community. In this latter case, funding usually comes largely from a restricted number of governmental 
funding bodies, and massive resources are invested in community-formation and identity politics. 
Researchers identify themselves as ‘rat-people’, ‘worm-people’ and ‘fly-people’, and much effort goes 
into making sure that all researchers working on the same organism know each other, attend common 
meetings and exchange data. As I argued above, this ethos is at the core of contemporary model 
organism biology: the very notion of model organism is linked to the construction of infrastructure and 
communities that can integrate data on a single species, with the future goal of using that as a reference 
point for a comparative understanding of organisms as wholes. Research on humans has a much longer 
and complex history, is located in several different types of settings ranging from research laboratories 
to clinics, involves countless more professionals than the few thousands involved in research on model 
organisms, and partly as a consequence of this is not focused on the integration of data as much as on 
understanding and treating specific diseases.x 
 
Issue 2: Meta-Data. Detailing Experimental Protocols 
A second headache for database curators is the lack of agreement on what information needs to be 
included about the experimental circumstances in which data are originally obtained – in other words, 
information about the provenance of data, the processes through which data was produced and 
formatted for dissemination (Bowker 2001, 664; Evans and Foster 2011). This information, technically 
 
 
referred to as meta-data, is crucial to assessing the evidential value and reliability of data found in a 
database. By accessing meta-data, users get to know who gathered the data of interest, the methods 
employed to do so and the research interests that motivated data production in the first place. These are 
all elements that help researchers to evaluate whether data are trustworthy, how they compare to other 
datasets available on the same phenomena and, as a result, what biological interpretation they could 
credibly support. Meta-data thus constitute ways to represent the tacit expertise underlying the 
production of data, in a way similar to the one described by Michael Lynch in the case of protocols 
(Lynch 2002). Contrary to Lynch’s case, however, the representation does not primarily serve 
administrative purposes: its most important function is to encourage the critical scrutiny of these 
practices by as wide a community of peers as possible, so as to facilitate the proliferation of different 
interpretations of the same data.  
 
The process of gathering meta-data is complicated by the fact that, even within model organism 
biology, different labs disagree on what elements are crucial in describing the provenance of data. 
Further, experimental protocols and procedures are constantly shifting, making it difficult to settle on 
fixed types of information as meta-data. Still, the curators of model organism databases argue for the 
importance of settling at least minimal standards for what counts as important information about an 
experiment.xi The most fundamental piece of information that needs to accompany each dataset is, 
unsurprisingly, the specific organism on which the data was obtained. The very idea of comparing data 
obtained on different organism depends on clearly identifying the species, and sometimes even the 
individual specimen, on which the data were originally collected. And yet, precisely on this crucial 
point curators find that clinical and biological researchers differ in how they conduct and describe 
experiments. Clinical researchers are perceived as frequently mixing organic materials coming from 
different organisms. According to the curators I interviewed, they often contaminate human samples 
 
 
with materials coming from other organisms – RNA probes, for instance – and do not care to specify 
this when writing up their results. They sometimes even fail to specify whether they are working on 
human cells or mouse cells, on the grounds that they are convinced, almost certain, that this will not 
matter for their conclusions. This attitude clashes with the strict standards for annotating experimental 
materials and procedures adopted within model organism biology. This sometimes results in curators 
refusing to include data in a cross-species database, because they cannot classify them according to the 
organism on which they were acquired. In the words of one curator: 
‘when people publish, they…a lot of times don’t tell you what protein they’re working on, 
whether it’s mouse or human. They’ll tell you the protein name, but that could be 99% identical 
between human and mouse and they won’t tell you which species it’s from. And so in that case 
we can’t annotate, we don’t know exactly the species’. 
 
Further, curators are committed to distinguishing results acquired through experimental procedures 
(referred in the quote below as ‘primary annotations’) from the interpretation of those results given by 
experimenters (‘author statement’). One of the main worries underlying the contamination of samples 
is that experimenters tend to decide, on the basis of their own experience and of the specific 
circumstances in which data are produced, whether contamination is relevant or not to interpreting the 
results. The reasons for this important decision are thus kept tacit and inaccessible to the users of 
databases that report those data, who are left with the only option of trusting the scientific judgment 
(and thus the beliefs and expertise) of the original data producers. This situation generates uneasiness 
among curators, since efficient data re-use is understood to involve the possibility to scrutinize (and if 
necessary, challenge) the beliefs and context in which data were originally produced, as noted by this 
curator: 
‘People will be interested in humans, but do the experiments in model organism or take a cloned 
 
 
human gene and work with it in a system that’s otherwise model organism in cultured cells or 
something. And it can be very, very difficult to find out which species the sequences came from, 
which species the cells came from, in a paper. It’s not that it’s necessarily unreasonable to infer 
that the human does the same thing as the mouse thing or the rat thing in many of these 
instances, but it would still be nice to know whether you stuffed the human gene into some 
cultured mouse cells or vice versa just in case there’s a difference and so that you know which 
one’s the primary experimental annotation and which one’s inferred from your belief that…that 
these genes correspond or are somehow equivalent.’ 
Remarkably, a consequence of such uneasiness is that human data on gene products are often annotated 
as author statements, because experiments are not carried out entirely on human tissue. Curators 
sometimes try to resolve this issue by emailing the authors of papers directly: 
  ‘Quite often I send an e-mail to the author. I’ll write and say, ‘can you tell me which species it’s 
from?’ And a lot of the time I get response, maybe 50% of the time you get response and you 
can annotate that then, whereas before you’d have to just chuck the paper away, can’t do 
anything with it.’ 
One way to explain the perceived difference in the ways in which clinicians and biologists annotate 
their experimental results is to think of the different priorities and commitments involved in their daily 
activities. It is often said that the medical project differs from the biological one in its emphasis on 
intervention and treatment: while clinicians aim to cure, biologists aim to explain. This distinction 
cannot be applied too neatly to experimental cultures in the two realms, since they both attempt to 
understand biological processes (whether general processes like metabolism and development or 
specific syndromes such as breast cancer) and to successfully manipulate organisms. However, the 
above remarks by curators on how experimenters annotate and assess their data point to some 
interesting differences in the ways in which biological and clinical experimental results are valued and 
 
 
used. These differences might be at least partly explained by the ways in which experimentation in the 
two realms is evaluated by funding bodies. Biologists are increasingly under pressure to produce results 
of social and economic relevance, and yet the quality of biological research is still primarily assessed 
through peer review of the procedures through which a new explanation was crafted and tested. As a 
result, enhancing the quality and credibility of experimental research in biology involves major efforts 
in documenting and validating the sources of the evidence used to back specific claims. By contrast, 
clinicians’ experimental results are explicitly valued not only for the biological insight that they 
generate, but also for their fruitfulness in supporting effective treatment of patients. This difference in 
priorities and evaluative cultures might contribute to explaining the relative disinterest of clinicians in 
documenting procedures and testing the reproducibility of results. 
 
Issue 3: Materials. Which Materials Get Standardized and How? 
Another reason that might account for the difference in experimental annotations concerns the very 
relationship built by researchers with the organisms that they study. This brings me to the third issue I 
wish to discuss, which is the experimental procedures used to select, manipulate and standardize 
organisms (both individual specimens and parts such as tissues, cell cultures, blood, organs). Within 
model organism biology, the standardization of organisms is of paramount importance: being able to 
access specimens that are genetically and/or phenotypically identical to the ones on which experiments 
are carried out is seen as crucial to validating experimental results and pursuing research that builds on 
previous efforts (Rosenthal and Ashburner 2002). Model organisms are standardized through two types 
of processes. The first consists of the processes of transformation from organisms found in the field to 
tractable laboratory specimens. The very act of transporting an organism into a laboratory environment 
occasions several changes to its biology (ranging from its physiology to its genome), due to the need to 
live in an environment where the basic rules of survival in the wild are subverted. For instance, most 
 
 
basic needs, such as food and light, are provided for and with much less variety than in the field; the 
organisms are protected from the vagaries of the elements and live in relative isolation from each other 
as well as from other forms of life. On top of the biological transformations due to this change of 
context and habits, which enhance the tractability of the organism by researchers who need to handle 
them, there are often genetic modifications specifically intended to make organisms more suited to the 
research goals at hand. The oncomouse is probably the best known case for research aimed to 
understand human biology (Clarke and Fujimura 1992; Murray 2010); Arabidopsis has been 
extensively modified to increase its susceptibility to changes in light and temperature, in the attempt to 
uncover the genetic basis of processes such as vernalization and photosynthesis. The second type of 
standardization processes used to produce model organisms is the one involved in the dissemination of 
specimens and related findings across research communities. For organisms to become favoured 
scientific materials, it is not sufficient that they are tractable in a laboratory environment and useful for 
the research that is carried out. Once that research starts to be disseminated across a wider community 
of experimenters, the organisms themselves need to be able to travel across different labs and research 
contexts, so that researchers can verify those results and/or further them through more experiments on 
precisely the same type of organism. The requirement to be physically sent to laboratories across the 
globe contributes to defining the characteristics of the organism selected for research: for instance, 
bigger organisms fare worse than smaller organisms and organisms that easily survive displacement are 
favoured.xii  
 
As illustrated by these procedures, the need to standardize guides and conditions all stages of 
researchers’ interactions with model organisms. This situation is quite different from the ways in which 
researchers interact with human subjects, and indeed neither of the two processes of standardization 
described above maps neatly onto the treatment of humans in clinical research. Let us consider the 
 
 
process of transformation first. It is true that human subjects are selected as subjects for research 
according to their biological characteristics, including sometimes their genetic make-up or their ethnic 
background. Some clinical studies look for ‘adequate’ populations across the globe – where ‘adequate’ 
means representative of the traits that researchers wish to study, and/or amenable to the kind of 
treatment and sampling required for clinical research purposes. Not surprisingly, however, the latter 
interpretation of what constitutes adequate populations is under heavy ethical scrutiny (Petryna 2009), 
not least because treatments are supposed to be tested on any group that might benefit from them, 
including ethnic minorities, affluent populations, children and pregnant women. Further, the very 
notion that human beings might be used as instruments for research, to the point of infringing on their 
basic rights (among which the right to privacy), is extremely controversial, and is often argued to 
require tighter regulation and more media attention than it is now (e.g. Waldby and Mitchell 2006). 
Another possible parallel to the process of transforming a model organism is the way in which patients 
are ‘prepared’ for participation in a clinical study, for instance through a specific diet and/or by 
imposing a set of appropriate behaviors and habits as a condition for participation (e.g. stopping to 
smoke or drinking alcohol). Even when taking this into account, however, human subjects cannot be 
viewed as undergoing physical modifications comparable to the transformation of model organism 
specimens so as to fit research needs – and again, there are excellent ethical and practical reasons why 
humans are not, nor should be, engineered in this way. Turning now to the process of dissemination, 
the parallels with the treatment of model organisms are more striking, even if still limited and 
controversial. While individual subjects are not routinely shipped around the world as a research 
commodity, samples of their tissues, cells or blood are disseminated through biobanks and thus selected 
on the basis of clear standards for what constitutes an acceptable donation (for instance in terms of its 
integrity, characteristic features, provenance and means through which it was collected). Still, such 
dissemination of samples is subject to stringent regulation that vary across national borders (Gere and 
 
 
Parry 2006; Kaye and Stranger 2009). Also, variability across human individuals plays an important 
role in clinical research – each sample is unique and not easily cloned or reproduced, which makes 
samples into a precious commodity whose dissemination is only agreed upon under specific 
circumstances (Parry 2004). Overall, ethical, practical and regulatory constraints make it impossible to 
think of human subjects in the same way as we think of specimens in non-human research. Indeed, this 
is the very reason why, despite the well-known ambiguities in inferring medical insights from research 
on model organisms and the controversy surrounding the use of animals in research, experimentation 
on non-human remains a stepping stone for clinical research. At least within Western scientific culture, 
the idea that humans deserve more respect and protection than non-humans has a strong hold. 
This set of considerations adds another important layer to curators’ worries about extensive differences 
in how researchers treat organisms. Remarkably, thinking about the ways in which organisms are 
manipulated shifts the focus away from a rigid divide between biological and clinical research, both of 
which are likely to use cross-species data. The relevant difference here is instead the one between 
researchers who study model organisms and researchers who study humans. Clinicians working on 
mice are much more likely to adhere to the practices recommended by database curators to describe 
their specimens, while researchers carrying out experiments on human subjects and their parts operate 
in quite a different experimental culture. It is then not surprising to note that, while clinicians working 
on humans were never officially involved in the effort to develop the GO, prominent representatives of 
the mouse community were among its founders (together with researchers working on fruit-flies and 
worms; Leonelli 2010b). 
 
Issue 4: Terminology. Extending the Gene Ontology 
The last issue I wish to discuss is the choice of terminology used to classify and retrieve data across 
 
 
organisms. For cross-species databases to work, such terminology should function as a lingua franca 
intelligible to all potential database users (Gene Ontology Consortium 2000). Already within model 
organism communities, the problem of choosing terms that different groups will recognize and 
understand is one of the most urgent issues confronted by curators.xiii Achieving terminological 
compatibility – if not integration – across the human/non-human boundary and across biological and 
clinical practice is even more daunting, especially given the amount of efforts already invested by the 
medical community towards terminological homologation (e.g. the Medical Subject Heading created 
by the National Library of Medicine to index medical literature, see website 
http://www.nlm.nih.gov/mesh/introduction.html). Attempts to integrate the terminologies used in 
medicine with the ones used in biology are under way since decades.  Some attempts, such as the ones 
focused on specific areas / diseases, are making headway, as illustrated by NCI Enterprise Vocabulary 
Services (EVS), a set of tools developed by National Cancer Institute to integrate molecular and 
clinical research on cancer (http://evs.nci.nih.gov/). To exemplify the issues that might emerge when 
merging vocabularies coming from model organism research and research on humans, I will focus 
briefly on the recent merger of GO terms with the Unified Medical Language System, a metathesaurus 
of 900.000 medical terms developed by the National Library of Medicine which is recognized as one of 
the most authoritative reference for standard medical terminology (Nelson et al 2002; Bodenreider 
2004). Despite curators’ published claims to the effect that the merger had been relatively smooth 
(Lomax and McCray 2004), my interviews with curators involved in this effort reveal that this attempt 
towards integration generated some interesting paradoxes and led to revisions of GO, many of which 
are still under way. For example, a key organizing principle within GO is to distinguish terms that 
describe a molecular function from terms that describe a biological process. Within medical discourse, 
such partition does not make sense, since the molecular function of gene products is automatically 
equated with a characterization of the biological process in which that gene is involved; thus, the 
 
 
UMLS nomenclature does not classify its terms according to it. Further, even in cases where terms 
overlap between the two nomenclatures, the meanings assigned to those terms might differ in a number 
of respects: the definition assigned to the terms might of course be different, a case where epistemic 
dissonance might be easily resolved through modifying the definitions; more problematically, however, 
the same term defined in the same way might acquire different meanings depending on its position in 
the semantic network of the nomenclature. To understand this point, one needs to know that terms in 
nomenclatures such as ULMS and GO are organized hierarchically through a series of relationships. 
Both systems rely heavily on the 'is_a' identity relation (as in 'nuclear membrane is a membrane'), yet 
differ in the other relationship types that they use. For instance, basic relationships in GO are 
mereological or ‘part_of’ relationships and functional relationships such as ‘regulates’. In contrast to 
GO, ULMS uses a wider and broader range of relationships including `physically related to,' `spatially 
related to,' `temporally related to,' `functionally related to,' and `conceptually related to'.xiv Given these 
differences in semantic structure, terms shift their meaning depending on where they are situated in the 
network – in much the same way as the interpretation of single words in everyday communication 
depends on the linguistic and social context in which they are used. 
 
Yet another issue emerges in relation to the process through which curators select which terms should 
be used to classify given sets of data. In biology, annotations tend to be based on peer-reviewed 
publications relating datasets to specific processes, functions or entities. In clinical research, however, 
it might be hard to find a direct, well-established link between a dataset and a term of interest – for 
instance, a disease. Still, there might be good reasons to suspect that such a link exists, and thus to 
annotate those data under the term referring to the disease in question. Trying to accommodate these 
different criteria is puzzling to curators trying to work on both realms, as evident in the following 
quote:  
 
 
  ‘The clinical research tends to give you more or less detailed GO terms, so, for example, 
epilepsy. You might, if you have nothing else for that protein but you know that that a mutation 
in that gene causes epilepsy then you could annotate to neuron development or something. So 
it’s a bit of a strange annotation to make, because you don’t know if it’s a direct link for that 
protein to cause…that protein is involved in neuron development, because it may be way 
downstream. But if you don’t have any other functional information for protein, then it’s good 
to make that annotation anyway.’ 
This brings us back to the divergence in priorities that I discussed with reference to data assessment 
and meta-data annotation, and enables me to add a further layer to it. Why would clinical researchers 
be satisfied with incomplete information in this case? One possible answer is that this is because, in 
their worldview, having some information is better than having no information at all. Biologists are 
typically more cautious in claiming causal links between biological processes, aware as they are of the 
risk of spurious correlations. Clinicians are more used to make causal claims and take account of 
information deemed to be relevant to a given disease without fully understanding the mechanisms 
causing it. This is because they do not have the luxury of waiting until detailed mechanistic 
understanding is achieved; they are under pressure to intervene on patients on the basis of the best 
knowledge available at any given time. Thus, in biomedical research, any hint that points to the 
etiology or treatment of abnormal human phenotypes merits mention; experimental research in this 
realm can always be characterized as largely exploratory.  
 
Finally, I wish to mention a more fundamental, conceptual problem with integrating nomenclatures 
across the human/non-human boundary. Databases such as GO have been built to focus on non-
pathogenic entities and processes – which are referred to as ‘normal’ (Gene Ontology Consortium 
2000). The reason for this is clear: model organisms are supposed to be representative for the biology 
 
 
of a wide set of organisms, and are thus conceptualized as ‘typical’ of ‘normal’ gene functions found in 
a given species. Clinical research on humans has almost the opposite connotation: because the main 
interest is in understanding and treating specific pathogenic conditions, cross-species research is 
centered on diseases and the vast majority of available human data document so-called ‘pathological 
states’. This situation causes serious problems when it comes to incorporate data on diseased organisms 
into GO, with the consequence of making cross-species databases potentially less interesting to clinical 
researchers, as one of the curators I interviewed makes clear:  
  ‘Some people at the National Cancer Institute have opted not to do very much with GO because 
it’s not ontology things, cancer or [GO is] explicitly excluding abnormal things such as 
oncogenesis or tumourogenesis that makes it unsuitable for their purposes. There are plenty of 
biologists who use it, but wish GO had more depth in this area or better annotations in that 
area’. 
This feature may account, at least in part, for the limited participation of clinicians working on human 
pathologies to the development of cross-species databases. At a more fundamental level, it raises the 
deep philosophical question of what constitutes ‘pathogenesis’ and ‘normality’ in the biological and 
clinical realms.xv An adequate discussion of this issue deserves more space that I can devote to it here. 
It is however an important dimension to mention in closing this section, as the way in which 
researchers answer this question deeply affects their conceptualization of organisms and of how 
experimental results should be collected, disseminated and interpreted. 
 
Conclusion: Identifying and Aligning Experimental Cultures in Biomedicine 
In her study of how databases are used to organize scientific work, Christine Hine has observed that the 
significance of these tools needs to be evaluated with reference to existing epistemic cultures, since 
 
 
‘while practices and outcomes of knowledge production may change with increasing use of information 
and communication technologies, such changes do not do away with existing framework’ (Hine 2006, 
290). In this paper, I have turned Hine’s argument on its head by using the study of database 
construction as a starting point to identify extant differences and tensions among the epistemic cultures 
that use these technologies. Examining curators’ perceptions of the difficulties involved in developing 
cross-species databases, and particularly in combining data coming from model organisms and humans, 
has enabled me to identify and discuss several characteristics of the complex interface between biology 
and medicine.xvi One set of the resulting observations reinforces the idea of a strong divergence in 
experimental practices, goals, and values between biologists and clinicians. For a start, there is a 
difference in research priorities and goals. Both sides aim to understand and change the world. Yet, 
biologists use their experimental skills as a way to understand organismal biology, while clinicians 
view the accumulation of biological understanding as essentially aimed to treat patients. This difference 
in emphasis is amplified by the evaluative cultures surrounding these two realms (issue 2). Clinicians 
are working in an environment where research is evaluated both for its contributions to medical 
knowledge and for its impact on treating patients. Despite the increasing push towards applied research, 
this is not the same for biologists, whose outputs are evaluated mainly through the quality of their 
publications. This in turn reinforces differences in how biologists and clinicians conduct research. For 
instance, clinicians tend to use data that biologists consider to be potentially unreliable, as illustrated by 
the controversies around the inclusion of high-throughput data in cross-species databases (issue 1) and 
the inclusion of causal, yet unproven, information in GO (issue 4). More generally, clinicians tend to 
value causal information that biologists do not see as conclusive, because of its potential value towards 
finding treatments. In their eyes, inserting such information in databases means increasing the chance 
of gathering useful clues towards understanding phenomena of interest; biologists seem to be more 
risk-averse, fearing that lowering standards for what counts as evidence will weaken the overall 
 
 
reliability of information found in databases. One final source of contrast is the way in which biologists 
and clinicians seem to direct their attention to different aspects of organismal biology altogether: 
‘normal states’ versus ‘pathological states’ (issue 4). Again, this is a difference in emphasis rather than 
a strict divide – after all, many of the mutants used to study healthy organisms might be defined as 
diseased, while clinicians obviously need an idea of what constitutes a healthy organism in order to 
identify and treat unhealthy ones. And yet, when added to the other evidence I mentioned, it seems to 
point to a rather stark separation between experimental cultures in medicine and biology. This simple 
picture is however disrupted by other aspects emerging from this study. Many sources of controversy 
highlighted by database curators stem not from cultural divergences between clinicians and biologists, 
but rather from differences in the research practices of experimenters who work with non-human 
organisms and experimenters who work with humans. Clearly, experimenting on humans brings 
ethical, financial and material constraints that are not present in model organism research. My analysis 
has highlighted the material aspects in particular, by showing the differences in how human and non-
human organisms are prepared and standardized for research (issue 3); and the difficulties in re-using 
human samples and reproducing results from clinical trials (issue 1). These material conditions give 
rise to differences in the ways in which researchers communicate and in the labels that they choose 
(issue 4). 
 
These results emerge from an analysis of curators’ struggle to understand the needs and working 
conditions of their users. Curators are dealing with two cross-cutting ways to identify user categories: 
they need to pay attention to the difference in research cultures underlying clinical and biological 
research; at the same time, they have to cater for model organism researchers and for researchers 
working on human subjects. This shows how databases are fast becoming crucial sites for the encounter 
of those diverging cultures, the identification of differences and the expression of conflict (which may 
 
 
or may not pave the way to its resolution). The recent deluge of genomic data is making it ever more 
difficult for biologists and clinicians to interpret the wealth of information found online in ways that 
help understanding the material bodies they work with – whether they are bodies of insects, plants, 
animals or humans. This process of aligning the informational with the material is specific to data-
intensive modes of experimental research and constitutes one of the foremost scientific challenges of 
the 21st century. The divides between biologists and clinicians on the one hand, and human and non-
human research on the other, make this process of alignment even more complex to achieve. The work 
done by curators is key to confronting this challenge. Curators are engaged in a process of alignment at 
all three levels: while attempting to foster the use of in silico information to understand organisms in 
vivo, they have to navigate the experimental cultures involved in biomedicine, and attempt to identify 
and align divergence between biological and clinical, and human and non-human, research. This 
process is crucial to what Keating and Cambrosio (2003) have described as the ongoing re-alignment of 
biology and medicine characteristic of post-genomic science. From the analysis above, it is evident that 
the production of adequate databases, and consensus on how these can and should be used, is a crucial 
platform for the development of cross-species research; and that cross-species research is in turn crucial 
to biomedical inquiry in all its forms, whether it is taking place in the lab or in the clinic, and whether it 
is focusing on the discovery of biological mechanisms or on therapeutic application. And indeed, how 
curators end up dealing with experimental pluralism in all its different forms is likely to have a huge 
effect on how different constituents of biomedical research relate to each other. The ways in which 
databases are structured, and the choice of which data gets included and how, can dilute or reinforce 
the differences in experimental cultures noted above. Sociological research on database development 
and use thus constitutes an important platform for the analysis and understanding of conflict, 
collaboration and integration in biomedicine. Further, it can improve our understanding of the relations 
between basic and applied research, and particularly of what constitutes translation in biomedicine and 
 
 
beyond. Keating and Cambrosio have already stressed the need to ‘understand the interactions between 
fundamental and clinical research in terms other than subordination or application’ (Keating and 
Cambrosio 2004, 368). The study of databases provides an excellent alternative to these binaries. We 
are not witnessing a simple movement from ‘bench to bedside’ here, nor a straightforward transfer of 
biological knowledge to medical practice. Rather, the focus on how data and materials are traded 
online, and on the related shifts in the skills and tools used to interpret such data and materials, 
facilitates the understanding of biomedicine as a complex web of practices which defies a neat 
classification into the very categories of ‘basic’ and ‘applied’. Research currently invested on the study 
of simple model organisms, such as Arabidopsis or C. elegans, plays as important a role within this 
web of practices as the recent attempts to develop genome-wide association studies for the study of 
cancer. Making sense of the intersections between human and non-human research is key for both 
scientists trying to further biomedicine and for social scientists interested in understanding their work – 
and as I hope to have shown, the development of cross-species databases is a good place to start. 
 
 
References  
 
Ankeny RA (2001) The natural history of C. elegans research. Nature Reviews Genetics 2: 474–8.  
 
Ankeny RA and Leonelli S (2011) What is so special about model organisms? Studies in the History 
and the Philosophy of Science: Part A. 42 (2): 313-32 
 
Baker KS and Millerand F (2010) Infrastructuring ecology: challenges in achieving data sharing. In 
Parker JN, Vermeulen N and Penders B (eds) Collaboration in the New Life Sciences. Ashgate.  
 
 
 
Bodenreider O (2004) The Unified Medical Language System (UMLS): Integrating biomedical 
terminology. Nucleic Acids Research 32: 267-270. 
 
Bolker JA (1995) Model systems in developmental biology. BioEssays 17: 451–5.  
 
Bowker GC (2001) Biodiversity datadiversity. Social Studies of Science 30 (5): 643-683. 
 
Buetow KH (2005) Cyberinfrastructure: empowering a "third way" in biomedical research. Science, 
308 (5723): 821 – 824. 
 
Bult CJ (2006) From information to understanding: the role of model organism databases in 
comparative and functional genomics. Animal Genetics 27 (1): 28-40. 
 
Canguilhem G (1991 [1966]) The Normal and the Pathological. New York: Zone Books. 
 
Chow-White PA and Garcia-Sanchos M (2011) Global genome databases bidirectional shaping and 
spaces of convergence: Interactions between biology and computing from the first DNA sequencers to 
global genome databases. Science, Technology and Human Values. Published online 27 February 2011. 
DOI: 10.1177/016224391039796 
 
Clarke AE and Fujimura JH (1992) The Right Tools for the Job. At Work in Twentieth-Century Life 
Sciences. Princeton, NJ: Princeton University Press. 
 
 
 
Davies G (2011) Playing dice with mice: building experimental futures in Singapore. New Genetics 
and Society, in press. 
 
Davies G (2010) Captivating behaviour: mouse models, experimental genetics and reductionist returns 
in the neurosciences. In Parry S and Dupré J (eds) Nature After the Genome. London: Sage. 
 
Davies RH (2004) The age of model organisms. Nature Reviews Genetics, 5: 69-76. 
 
Editorial Nature (2009) The sharing principle. Nature 459:752. 
 
Evans JA and Foster JG (2011) Metaknowledge. Science 331 (6018): 721-725. 
 
Gene Ontology Consortium (2000) Gene Ontology: tool for the unification of biology. Nature Genetics 
25: 25-29. 
 
Gene Ontology Website (accessed April 2010), http://www.geneontology.org 
 
Gere C and Parry B (2006) The flesh made word: banking the body in the age of information. 
Biosocieties 1 (1): 83-98. 
 
Hey T and Trefheten AE (2005) Cyberinfrastructure for e-science. Science 308: 817-821. 
 
Hilgartner S (1995) Biomolecular databases: new communication regimes for biology? Science 
Communication 17: 240-263. 
 
 
 
Hine C (2006) Databases as scientific instruments and their role in the ordering of scientific work. 
Social Studies of Science 36(2): 269-298. 
 
Howe D et al (2008) Big data: the future of biocuration. Nature 455: 47-50. 
 
International Arabidopsis Informatics Consortium (2010) An international bioinformatics infrastructure 
to underpin the Arabidopsis community. Plant Cell  22(8): 2530-2536. 
 
Ioannidis et al (2009) Genome-wide association studies for complex traits: consensus, uncertainty and 
challenges. Nature Reviews Genetics 9: 356-369. 
 
Kaye J and Stranger M (ed) (2009) Principles and Practice in Biobank Governance. London: Ashgate.  
 
Keating P and Cambrosio A (2003) Biomedical Platforms: Realigning the Normal and the 
Pathological in Late-Twentieth-Century Medicine. Cambridge, MA: MIT Press. 
 
Keating P and Cambrosio A (2004) Does Biomedicine Entail the Successful Reduction of Pathology to 
Biology? Perspectives in Biology and Medicine 47(3): 357-371. 
 
Kohler RE (1994) Lords of the fly: Drosophila genetics and the experimental life. Chicago, IL: 
University of Chicago Press.  
 
 
 
Kohli-Laven N, Bourret P, Cambrosio A and Keating P (2011) Cancer clinical trials in the era of 
genomic signatures: biomedical innovation, clinical utility, and regulatory-scientific hybrids. Social 
Studies of Science 41(4) 487–513 
 
Leigh Star S and Rhleder K (1996) Steps towards an ecology of infrastructure: design and access for 
large information spaces. Information Systems Research 7 (1): 63-92.  
 
Lenoir T (1999) Shaping biomedicine as an information science. In Bowden ME, Hahn TB and 
Williams RV (eds) Proceedings of the 1998 Conference on the History and Heritage of Science 
Information Systems. Medford, NJ: Information Today, Inc., ASIS Monograph Series, 27-45. 
 
Leonelli S (2009) Centralising labels to distribute data: the regulatory role of genomic consortia. In 
Atkinson P, Glasner P and Lock M (eds) The Handbook for Genetics and Society: Mapping the New 
Genomic Era. Routledge, London, pp. 469-485. 
 
Leonelli S (2010a) Packaging data for re-use: databases in model organism biology. In Howlett P and 
Morgan MS (eds) How Well Do Facts Travel? The Dissemination of Reliable Knowledge. Cambridge, 
UK: Cambridge University Press. 
 
Leonelli S (2010b) Documenting the emergence of bio-ontologies: or, why researching bioinformatics 
requires HPSSB. History and Philosophy of the Life Sciences, 32 (1): 105-126. 
 
Loewy I (1986) Between Bench and Bedside: Science, Healing, and Interleukin-2 in a Cancer Ward. 
Cambridge, MA: Harvard University Press.  
 
 
 
Lomax J and McCray AT (2004) Mapping the Gene Ontology into the Unified Medical Language 
System. Comparative and Functional Genomics 5: 354-361. 
 
Lynch, M (2002) Protocols, practices and the reproduction of techniques in molecular biology. The 
British Journal of Sociology 53 (2): 203-220. 
 
McMullen PD, Morimoto RI and Amaral LAN (2010) Physically grounded approach for estimating 
gene expression from microarray data. PNAS 10(31): 13690-13695.   
 
Murray, F (2010) The Oncomous that roared: hybrid exchange strategies as a source of distinction at 
the boundary of overlapping institutions. American Journal of Sociology 116(2): 341-388. 
 
Nelson SJ, Powell T, Srinivasan S and Humphreys BL (2002) The Unified Medical Language System 
(UMLS) project. In Kent A and Hall CM (eds) Encyclopedia of Library and Information Science. New 
York: Marcel Dekker, Inc., 369-378. 
 
National Human Genome Research Institute, National Institute of Health Website (accessed December 
2009) http://www.genome.gov/10001735 
 
O'Malley MA (2008) Exploratory experimentation and scientific practice: metagenomics and the 
proteorhodopsin case. History and Philosophy of the Life Sciences 29(3): 337–358. 
 
Parry B (2004) Trading the Genome. New York: Columbia University Press. 
 
 
 
Petryna A (2009) When Experiments Travel: Clinical Trials and the Global Search for Human 
Subjects. Princeton, New Jersey: Princeton University Press. 
 
Quirke V and Gaudillière JP (2008) The era of biomedicine: science, medicine, and public health in 
Britain and France after the Second World War. Medical History 52(4): 441-452. 
 
Rader K (2004) Making Mice. Princeton, NJ: Princeton University Press. 
 
Rhee SY and Crosby B (2005) Biological databases for plant research. Plant Physiology 138(1): 1–3. 
 
Rhee SY (2004) Carpe diem: retooling the ‘‘publish or perish’’ model into the ‘‘share and survive’’ 
model. Plant Physiology 134: 543–547. 
 
Rogers S and Cambrosio A (2007) Making a new technology work: the standardization and regulation 
of microarrays. Yale Journal of Biology and Medicine 80: 165-178. 
 
Rosenthal N and Ashburner M (2002) Taking stock of our models: the function and future of stock 
centers. Nature Reviews Genetics 3: 711–7. 
 
Spradling A et al (2006) New roles for model genetic organisms in understanding and treating human 
disease: report from the 2006 Genetics Society of America Meeting. Genetics 172: 2025-2032.  
 
Star SL and Griesemer JR (1989) Institutional ecology, 'translations' and boundary objects: amateurs 
 
 
and professionals in Berkeley's Museum of Vertebrate Zoology, 1907-39. Social Studies of 
Science 19 (3): 387–420. 
 
Stein LD (2008) Towards a cyberinfrastructure for the biological sciences: progress, visions and 
challenges. Nature Reviews Genetics, 9 (9):678-688.  
 
Stein LD et al (2002) The Generic Genome Browser: a building block for a model organism system 
database. Genome Research 12: 1599-1610. 
 
Sturtevant A (1954) The social implications of the genetics of man. Science 120: 60. 
 
Taylor C et al (2008) Promoting coherent minimum reporting guidelines for biological and biomedical 
investigations: the MIBBI project. Nature Biotechnology 26, 8: 889-896. 
 
Unified Medical Language System Website (accessed 2010) 
http://www.nlm.nih.gov/research/umls/knowledge_sources/index.html#semantic  
 
Waldby C and Mitchell R (2006) Tissue Economies: Blood, Organs and Cell Lines in Late Capitalism. 
Durham and London: Duke University Press.  
 
Wouters P and Schröder P (eds) (2003) The Public Domain of Digital Research Data Amsterdam: 
NIWI-KNAW. 
 
                                                
i A referee has pointed out that instead of focusing on differences between  experimental cultures, thus study could have 
 
 
                                                                                                                                                                 
interrogated what constitutes ‘the same practice’ across those communities. While agreeing that this would have constituted 
another interesting take on my data, I am not able to incorporate this into the already extensive scope of this paper. 
ii The importance of model organisms as tools for interdisciplinary collaboration has also been stressed by several 
pioneering STS studies, including most famously the notions of model organisms as ‘right tools for the job’ (Clarke & 
Fujimura 1992) and ‘boundary objects’ (Star and Griesemer 1989). 
iii It is true that the founders of these model organism communities grounded their interdisciplinary approach firmly on 
genetic studies, thus becoming vulnerable to anti-reductionist critiques (Bolker 1995).  Nevertheless, historical research 
shows how strongly these scientists were committed to the long-term ideal of interdisciplinary integration (Ankeny and 
Leonelli 2011). 
iv It is tempting to define model organisms as non-human organisms that are used to understand human biology, and of 
course model organisms are often used to that aim. However, it is important to remember that this is not always the case. 
Research on plants, for instance, is mainly focused on improving food production and acquiring new sources of energy; 
while some research on animals aims to make sense of specific features of their biology, which could be put to use in human 
societies (e.g. dog and sheep breeding, egg production, migration patterns in fish and bird populations). My definition of 
model organisms, based  on the extent to which they are researched and understood rather than on what they are meant to 
represent, is thus broader and more satisfactory than a definition based on their role as human models.  
v See the webpage of the National Human Genome Research Institute, listing the main community databases funded by the 
National Institute of Health (http: www.genome.gov/10001837 ). 
vi The important role played by these databases in model organism research is underscored by the strongly critical reactions 
by biologists to recent announcements of funding cuts. TAIR in particular is under threat as NSF funding for the project has 
been phased out, and the vehement protests of the Arabidopsis research community resulted in the formation of an 
International Arabidopsis Informatics Consortium , which recommended the continuation of TAIR under the ‘new’ name 
Arabidopsis Information Resource (International Arabidopsis Informatics Consortium 2010). 
vii Details on the history, personnel and characteristics of GO can be found in Leonelli (2009, 2010b). 
viii Studies using richer models of the process by which microarray data are constructed claim to produce much better and 
more reproducible results of even existing microarray data (McMullen et al, 2010). 
ix For an in-depth discussion of the characteristics of exploratory research, see O’Malley (2008). 
x Research on mice represents an extremely interesting middle ground between the ethos characterizing model organism 
 
 
                                                                                                                                                                 
biology and the ethos of clinical research, which deserves a whole study in its own right. As in other model organism 
communities, mouse-people form a tight network and strive to build infrastructures that will ensure the standardization and 
centralized access to specimens, protocols and data. At the same time, these efforts are routinely undermined by the 
scientific, social and economic context in which research on mice takes place, which tends to be extremely competitive and 
fragmented into small communities with little financial and social incentive to communicate with each other (see for 
instance the debates around the creation of a centralized stock centre, Editorial Nature 2009). For an in-depth study of 
current research on mice, see Gail Davies (e.g. 2010).   
xi An example of this is the MIBBI project (Taylor et al 2008). It must be noted that, as remarked by a referee, few of these 
discussions on standards are applied within databases as yet. The level of standardization adopted by Gene Ontology 
curators is one of the highest among model organism databases.  
xii It is no wonder that plants, whose specimens can be sent around in the form of seeds, are among the best stocked and 
standardised organisms (Leonelli 2007), while mice and rat researchers rely both on whole specimen collections and  tissue 
cultures (Davies 2011). 
xiii The very success of the GO, as of all bio-ontologies within the Open Biomedical Ontologies Consortium, stems from 
attempts to solve this problem (Leonelli 2010b). 
xiv From the GO and ULMS websites, accessed in March 2010. 
xv Clearly, GO is not sharing in George Canguilhem’s insight that that 'the menace of disease is one of the components of 
health' (1991). 
xvi Admittedly, these issues are likely to emerge in any research environment making use of biological databases, and are 
thus not per se characteristic of the case of cross-species databases. For instance, biologists working on different organisms 
can strongly disagree on the reliability of microarray experiments; picking meta-data is an arduous task no matter which 
types of data one is trying to disseminate and re-use; and the process of labeling data for travel is always charged with 
specific interests, values and beliefs. However, looking at the specific manifestations of these problems in the development 
of cross-species databases can teach us much about the intersections between medicine and biology, as I argue here. 
